Global Good and Motic Announce AI-Powered Microscope at MEDICA 2017
|
By LabMedica International staff writers Posted on 15 Nov 2017 |

Image: The EasyScan GO AI-powered microscope is designed to help fight the spread of drug-resistant malaria and assist in case management (Photo courtesy of Motic).
Advanced microscope designer and manufacturer Motic China Group Co., Ltd. (Xiamen, China), has announced at MEDICA 2017 that it will partner with the Global Good Fund (Bellevue, WA, USA), a collaboration between Intellectual Ventures and Bill Gates, to develop technologies for humanitarian impact. The collaboration will create and distribute the EasyScan GO, a breakthrough AI-powered microscope to fight the spread of drug-resistant malaria and assist in case management.
Motic specializes in manufacturing conventional compound microscopes, while Global Good is dedicated to inventing technology for humanitarian impact by collaborating with leading humanitarian organizations, forward-looking governments, research institutions, and corporate and private sector partners. Both Motic and Global Good will collaborate to create and distribute the EasyScan GO AI-powered microscope, which uses custom image recognition software to identify and count malaria parasites in a blood smear in as little as 20 minutes.
Accurate detection of severe and drug-resistant cases requires analysis of a blood smear by a WHO-certified expert microscopist, which takes roughly 20 minutes per slide. Automating the process with an intelligent microscope can alleviate the shortfall of trained personnel in under-resourced countries. Field tests of an early prototype of the microscope presented at the International Conference on Computer Vision (ICCV) showed that the machine-learning algorithm developed by Global Good is as reliable as an expert microscopist.
The EasyScan GO is currently being trained to recognize all species of malaria and other parasites and traits commonly found on a blood film, including Chagas disease, microfilaria and sickle cell. The team will also explore its application to other sample types, such as sputum, feces and tissue, as well some forms of cancer.
“This collaboration, combining Global Good’s impact invention focus with Motic’s engineering, manufacturing and distribution capabilities, represents the type of innovative healthcare solution that is needed to improve health in emerging and low-income markets,” said Maurizio Vecchione, Intellectual Ventures’ Executive Vice President of Global Good and Research. “By distributing and commercializing an intelligent microscope, Global Good and Motic are creating a future where quality diagnosis of multiple diseases is within reach for everyone everywhere.”
“Malaria is one of the hardest diseases to identify on a microscope slide,” said David Bell, Director of Global Health Technologies supporting Global Good. “By putting machine learning-enabled microscopes in the hands of laboratory technicians, we can overcome two major barriers to combating the mutating parasite—improving diagnosis in case management and standardizing detection across geographies and time.”
“Our goal in integrating Global Good’s advanced software into Motic’s high-quality, affordable digital slide scanner is to simplify and standardize malaria detection,” said Richard Yeung, Vice President of Motic China. “Success with the most difficult-to-identify disease paves the way for the EasyScan product line to excel at almost any microscopy task and to detect other major diseases that affect developed and emerging markets alike.”
Motic specializes in manufacturing conventional compound microscopes, while Global Good is dedicated to inventing technology for humanitarian impact by collaborating with leading humanitarian organizations, forward-looking governments, research institutions, and corporate and private sector partners. Both Motic and Global Good will collaborate to create and distribute the EasyScan GO AI-powered microscope, which uses custom image recognition software to identify and count malaria parasites in a blood smear in as little as 20 minutes.
Accurate detection of severe and drug-resistant cases requires analysis of a blood smear by a WHO-certified expert microscopist, which takes roughly 20 minutes per slide. Automating the process with an intelligent microscope can alleviate the shortfall of trained personnel in under-resourced countries. Field tests of an early prototype of the microscope presented at the International Conference on Computer Vision (ICCV) showed that the machine-learning algorithm developed by Global Good is as reliable as an expert microscopist.
The EasyScan GO is currently being trained to recognize all species of malaria and other parasites and traits commonly found on a blood film, including Chagas disease, microfilaria and sickle cell. The team will also explore its application to other sample types, such as sputum, feces and tissue, as well some forms of cancer.
“This collaboration, combining Global Good’s impact invention focus with Motic’s engineering, manufacturing and distribution capabilities, represents the type of innovative healthcare solution that is needed to improve health in emerging and low-income markets,” said Maurizio Vecchione, Intellectual Ventures’ Executive Vice President of Global Good and Research. “By distributing and commercializing an intelligent microscope, Global Good and Motic are creating a future where quality diagnosis of multiple diseases is within reach for everyone everywhere.”
“Malaria is one of the hardest diseases to identify on a microscope slide,” said David Bell, Director of Global Health Technologies supporting Global Good. “By putting machine learning-enabled microscopes in the hands of laboratory technicians, we can overcome two major barriers to combating the mutating parasite—improving diagnosis in case management and standardizing detection across geographies and time.”
“Our goal in integrating Global Good’s advanced software into Motic’s high-quality, affordable digital slide scanner is to simplify and standardize malaria detection,” said Richard Yeung, Vice President of Motic China. “Success with the most difficult-to-identify disease paves the way for the EasyScan product line to excel at almost any microscopy task and to detect other major diseases that affect developed and emerging markets alike.”
Latest Medica 2017 News
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more








